Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 15/20 | 0.47 |
| ▸ | KDR | P35968 | 14/20 | 0.47 |
| ▸ | KIF5B | P33176 | 12/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | FLT1 | P17948 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | GAK | O14976 | 1/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.44 |
| ▸ | STK10 | O94804 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.44 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.44 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2476964 | 0.87 | RET (0.55) | RETKDRKIF5BFGFR1FLT1 | |
| SCHEMBL29801726 | 0.84 | EGFR (0.53) | RETKDRKIF5BEGFRJAK3 | |
| SCHEMBL216888 | 0.84 | EGFR (0.53) | RETKDRKIF5BEGFRJAK3 | |
| Hydrochloric Acid SCHEMBL28006468 | 0.83 | EGFR (0.52) | RETKDRKIF5BEGFRJAK3 | |
| SCHEMBL31469297 | 0.81 | EGFR (0.49) | RETKDRKIF5BFGFR1FLT1 | |
| SCHEMBL28704127 | 0.81 | EGFR (0.49) | RETKDRKIF5BFGFR1FLT1 | |
| SCHEMBL21614043 | 0.81 | RET (0.43) | RETKDRKIF5BFGFR1FLT1 | |
| SCHEMBL20355452 | 0.81 | JAK3 (0.51) | RETKDRKIF5BFGFR1FLT1 | |
| SCHEMBL8807100 | 0.81 | EGFR (0.41) | RETKDRKIF5BFGFR1FLT1 | |
| SCHEMBL7802744 | 0.81 | EGFR (0.53) | RETKDRKIF5BEGFRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180208584-A1 | 1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS | SABILA BIOSCIENCES LLC (US) | 2018-07-26 | — | — | US | disclosed |
| US-20180016259-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ASTRAZENECA AB (SE) | 2018-01-18 | — | — | US | disclosed |
| US-9718806-B2 | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | ASTRAZENECA AB (SE) | 2017-08-01 | — | — | US | disclosed |
| US-20160340342-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ASTRAZENECA AB (SE) | 2016-11-24 | — | — | US | disclosed |
| US-9375432-B2 | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | ASTRAZENECA AB (SE) | 2016-06-28 | — | — | US | disclosed |
| US-20150320751-A1 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor | ASTRAZENECA AB (SE) | 2015-11-12 | — | — | US | disclosed |
| US-9066979-B2 | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | ASTRAZENECA AB (SE) | 2015-06-30 | — | — | US | disclosed |
| US-20140255428-A1 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor | ASTRAZENECA AB (SE) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320751-A1 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor | EGFR, ABL1, ERBB2 | RET 16/4885KDR 78/4885KIF5B 1887/4885 |
| US-20180208584-A1 | 1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS | EGFR, BRCA1, PTPRJ | RET 165/4885KDR 2100/4885KIF5B 2309/4885 |
| US-20180016259-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | EGFR, ERBB2, ABL1 | RET 31/4885KDR 63/4885KIF5B 1603/4885 |
| US-20160340342-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | EGFR, ABL1, ERBB2 | RET 16/4885KDR 78/4885KIF5B 1887/4885 |
| US-20140255428-A1 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor | EGFR, ERBB2, ABL1 | RET 27/4885KDR 74/4885KIF5B 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.